HMBD-002
1 abstract
Abstract
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas Southwestern Medical Center, Dallas, TX, Stanford Cancer Center GI Surgical Oncology, Stanford, CA, Cedars-Sinai Cancer Institute, Los Angeles, CA, Cedars-Sinai Medical Center, Los Angeles, CA,